×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
PDSB – pds biotechnology corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
PDSB
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/28
08:45 am
pdsb
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
Medium
Report
PDS Biotech Announces Presentation of Preliminary Results from Phase 2 Study of IL-12 Tumor Targeted Immunocytokine (PDS01ADC) in 3rd Line Metastatic Castration Resistant Prostate Cancer by the NCI
1/22
09:15 am
pdsb
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 [Yahoo! Finance]
Low
Report
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101 [Yahoo! Finance]
1/22
08:45 am
pdsb
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
Low
Report
PDS Biotech Announces New U.S. Patent Covering Technology Underlying PDS0101
1/9
08:45 am
pdsb
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
Medium
Report
PDS Biotech Announces FDA Alignment on use of Progression Free Survival (PFS) as Primary Endpoint
12/9
08:00 am
pdsb
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
High
Report
PDS Biotech Announces New Composition of Matter Patent for PDS0101 in Japan
12/2
08:30 am
pdsb
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
Medium
Report
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
11/25
01:15 pm
pdsb
PDS Biotechnology (NASDAQ:PDSB) had its price target lowered by analysts at B. Riley from $5.00 to $3.00. They now have a "buy" rating on the stock.
Low
Report
PDS Biotechnology (NASDAQ:PDSB) had its price target lowered by analysts at B. Riley from $5.00 to $3.00. They now have a "buy" rating on the stock.
11/13
01:39 pm
pdsb
PDS Biotechnology (NASDAQ:PDSB) had its price target raised by analysts at HC Wainwright from $13.00 to $15.00. They now have a "buy" rating on the stock.
Low
Report
PDS Biotechnology (NASDAQ:PDSB) had its price target raised by analysts at HC Wainwright from $13.00 to $15.00. They now have a "buy" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
11/13/2025
07:30 am
pdsb
pds biotechnology corporation
BEAT
Report
-11.3%
pds biotechnology corporation
8/13/2025
07:00 am
pdsb
pds biotechnology corporation
BEAT
Report
-6.5%
pds biotechnology corporation
5/14/2025
07:30 am
pdsb
pds biotechnology corporation
BEAT
Report
-2.2%
pds biotechnology corporation
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/28
08:51 am
pdsb
Form 8-K PDS Biotechnology Corp For: Jan 28
Medium
Report
Form 8-K PDS Biotechnology Corp For: Jan 28
1/22
08:51 am
pdsb
Form 8-K PDS Biotechnology Corp For: Jan 22
Low
Report
Form 8-K PDS Biotechnology Corp For: Jan 22
1/9
08:51 am
pdsb
Form 8-K PDS Biotechnology Corp For: Jan 09
Medium
Report
Form 8-K PDS Biotechnology Corp For: Jan 09
12/12
04:31 pm
pdsb
Form S-8 PDS Biotechnology Corp
Medium
Report
Form S-8 PDS Biotechnology Corp
12/9
08:06 am
pdsb
Form 8-K PDS Biotechnology Corp For: Dec 09
High
Report
Form 8-K PDS Biotechnology Corp For: Dec 09
12/2
08:36 am
pdsb
Form 8-K PDS Biotechnology Corp For: Dec 02
Medium
Report
Form 8-K PDS Biotechnology Corp For: Dec 02
11/13
07:36 am
pdsb
Form 8-K PDS Biotechnology Corp For: Nov 13
High
Report
Form 8-K PDS Biotechnology Corp For: Nov 13
11/12
09:12 am
pdsb
Form 8-K PDS Biotechnology Corp For: Nov 11
Low
Report
Form 8-K PDS Biotechnology Corp For: Nov 11
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/14
Q1/2019 3/31/2019 EPS 1.470 ZacksConsensus N/A ActVsEst N/A - N/A
41.4%
10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%
2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%
7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%
10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%
11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%
12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%
3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%
9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%
12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%
10/3 PDS Biotechnology Corp. Announces Clinical Collaboration with Merck 31.3%
2/5 PDS Biotechnology to Present at the 2020 BIO CEO & Investor Conference 16.3%
7/30 Form 8-K PDS Biotechnology Corp For: Jul 29 11.8%
10/22 PDS Biotechnology Completes Manufacturing of Clinical Batches of PDS0101 10.7%
11/25 PDS Biotechnology to Present at the World Vaccine & Immunotherapy Congress West Coast 2019 7.5%
12/3 PDS Biotechnology to Present at the 12th Annual LD Micro Main Event 6.7%
3/2 Form SC 13D PDS Biotechnology Corp Filed by: NETSCIENTIFIC PLC 6.6%
9/19 PDS Biotechnology Reports Clinical Data for Its Novel Immunotherapy PDS0101 in Follow up to Phase 1 Human Trial 6.1%
12/23 PDS Biotechnology Corporation (NASDAQ: PDSB) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $10.00 price target on the stock. 5.4%
TOP News Decliners
2/11
PDS Biotechnology Corporation Announces Pricing of Public Offering of Approximately $12 Million of Shares of Common Stock
-25.8%
9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%
12/17 Form S-1 PDS Biotechnology Corp -14.9%
3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%
12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%
2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%
11/14 Form S-8 PDS Biotechnology Corp -12.7%
4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%
11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%
6/4 Form S-8 PDS Biotechnology Corp -8.4%
9/24 Form 8-K PDS Biotechnology Corp For: Sep 24 -15.4%
12/17 Form S-1 PDS Biotechnology Corp -14.9%
3/9 PDS Biotechnology Corporation (NASDAQ: PDSB) is now covered by analysts at Noble Financial. They set an "outperform" rating and a $5.45 price target on the stock. -14.2%
12/13 Form 8-K PDS Biotechnology Corp For: Dec 11 -13.5%
2/11 Form FWP PDS Biotechnology Corp Filed by: PDS Biotechnology Corp -12.7%
11/14 Form S-8 PDS Biotechnology Corp -12.7%
4/16 PDS Biotechnology Initiates Novel Vaccine Development Programs For COVID-19 and Universal Influenza; Delay of PDS0101 VERSATILE-002 trial -9.8%
11/25 Form 8-K PDS Biotechnology Corp For: Nov 25 -8.8%
6/4 Form S-8 PDS Biotechnology Corp -8.4%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: